Estradiol benzoate/testosterone isobutyrate: Difference between revisions

Estradiol benzoate /
testosterone isobutyrate
	Estradiol benzoate (top) and; testosterone isobutyrate (bottom)
Combination of
Estradiol benzoate	Estrogen
Testosterone isobutyrate	Androgen; Anabolic steroid
Clinical data
Trade names	Femandren M, Folivirin
Other names	EB/TiB; EB/TiB
Routes of; administration	Intramuscular injection
Identifiers
CAS Number	72708-14-6;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 06:06, 8 November 2023

Estradiol benzoate/testosterone isobutyrate (EB/TiB), sold under the brand names Femandren M and Folivirin, is an injectable combination medication of estradiol benzoate (EB), an estrogen, and testosterone isobutyrate (TiB), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women.^[1]^[2]^[3]^[4]^[5]^[6]^[7] It is provided in the form of 1 mL ampoules containing 2.5 mg estradiol benzoate and 25 mg testosterone isobutyrate in a microcrystalline aqueous suspension and is administered by intramuscular injection once every 4 to 6 weeks.^[6]^[8] EB/TiB reportedly has a duration of about 14 to 21 days.^[9]

The medication is available only in the Czech Republic and Slovakia.^[10]^[11]^[12]^[13] EB/TiB was originally developed and marketed by the Swiss pharmaceutical company Ciba and was introduced for medical use by 1953,^[6] following the development of testosterone isobutyrate in 1952.^[14] It was intermittently manufactured by Spofa^[15] and then Biotika^[3] and is now manufactured by BB Pharma.^[10]^[11]^[16]

The effect of EB/TiB on gonadotropin levels in postmenopausal women have been studied.^[17]

An oral tablet product with the same brand name of Femandren, containing ethinylestradiol and methyltestosterone, was marketed around the same time as Femandren M, and should not be confused with the injectable formulation.^[18]^[4]^[5]

v
t
e
Androgen replacement therapy formulations and dosages used in women
Route	Medication	Major brand names	Form	Dosage
Oral	Testosterone undecanoate	Andriol, Jatenzo	Capsule	40–80 mg 1x/1–2 days
	Methyltestosterone	Metandren, Estratest	Tablet	0.5–10 mg/day
	Fluoxymesterone	Halotestin	Tablet	1–2.5 mg 1x/1–2 days
	Normethandrone^a	Ginecoside	Tablet	5 mg/day
	Tibolone	Livial	Tablet	1.25–2.5 mg/day
	Prasterone (DHEA)^b	–	Tablet	10–100 mg/day
Sublingual	Methyltestosterone	Metandren	Tablet	0.25 mg/day
Transdermal	Testosterone	Intrinsa	Patch	150–300 μg/day
Transdermal	Testosterone	AndroGel	Gel, cream	1–10 mg/day
Vaginal	Prasterone (DHEA)	Intrarosa	Insert	6.5 mg/day
Injection	Testosterone propionate^a	Testoviron	Oil solution	25 mg 1x/1–2 weeks
	Testosterone enanthate	Delatestryl, Primodian Depot	Oil solution	25–100 mg 1x/4–6 weeks
	Testosterone cypionate	Depo-Testosterone, Depo-Testadiol	Oil solution	25–100 mg 1x/4–6 weeks
	Testosterone isobutyrate^a	Femandren M, Folivirin	Aqueous suspension	25–50 mg 1x/4–6 weeks
	Mixed testosterone esters	Climacteron^a	Oil solution	150 mg 1x/4–8 weeks
	Mixed testosterone esters	Omnadren, Sustanon	Oil solution	50–100 mg 1x/4–6 weeks
	Nandrolone decanoate	Deca-Durabolin	Oil solution	25–50 mg 1x/6–12 weeks
	Prasterone enanthate^a	Gynodian Depot	Oil solution	200 mg 1x/4–6 weeks
Implant	Testosterone	Testopel	Pellet	50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: ^a = Mostly discontinued or unavailable. ^b = Over-the-counter. Sources: See template.

References

^ "FOLIVIRIN Injekční suspenze, Příbalová Informace - Informace Pro Uživatele" [FOLIVIRIN Suspension for injection, Package Information - Information For Users] (PDF). Biotika A.S. (in Czech). Czech Republic: State Institute for Drug Control. Archived from the original (PDF) on 2019-05-20. Retrieved 2019-05-20.
^ Kubíková D (2014). "Menopauzální symptomy a hormonální substituční terapie" [Menopausal symptoms and hormone replacement therapy]. Praktické Lékárenství (in Czech). 10 (2): 68–73. ISSN 1801-2434.
^ ^a ^b Josef M (14 May 2010). "Farmakoterapie endokrinních onemocnění a léčba kortikosteroidy" [Pharmacotherapy of endocrine diseases and treatment with corticosteroids]. Farmakoterapie vnitřních nemocí [Pharmacotherapy of internal diseases] (4th ed.). Grada Publishing a.s. pp. 380–. ISBN 978-80-247-9524-9. In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect.
^ ^a ^b Arends G, Zörnig H, Hager H, Frerichs G, Kern W (14 December 2013). Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1163–. ISBN 978-3-662-36329-4.
^ ^a ^b Hager HH, Kern W, List PH, Roth HJ (29 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 109, 141, 178, 185. ISBN 978-3-662-25655-8.
^ ^a ^b ^c Ciba Symposium: 1953/57:Index. Ciba. 1953. p. 197. Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone ; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines.
^ Aeppli H, Herrmann FU (1953). "Kombinierte Androgen-Oestrogenbehandlung mit Kristallsuspensionen". Gynecologic and Obstetric Investigation. 136 (5): 290–295. doi:10.1159/000308340. ISSN 1423-002X.
^ Horsky J, Presl J (6 December 2012). "Climacteric and Menopause". Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 146–. ISBN 978-94-009-8195-9.
^ Ufer J (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis [Hormone Therapy in Gynecology: Principles and Practice] (in German) (5th ed.). de Gruyter. p. 276. ISBN 978-3110066647. OCLC 924728827.
^ ^a ^b "Estradiol: Uses, Dosage & Side Effects". Drugs.com.
^ ^a ^b "Testosterone Injections: Uses, Side Effects & Warnings". Drugs.com.
^ Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2133–2134. ISBN 978-0-85369-840-1.
^ "Home". micromedexsolutions.com.
^ Drescher H (April 1952). "Unsere Erfahrungen mit einer neuartigen Testosteron-isobutyrat-Kristallsuspension" [Experiences with a New Testosterone Isobutyrate Crystal Suspension]. Dtsch. Med. Wochenschr. (in German). 77 (14): 431–2. doi:10.1055/s-0028-1115985. PMID 12988767.
^ Schreiber V (6 December 2012). "Thyroxine Binding to Anterior Pituitary Proteins in Vitro: Correlation with Anterior Pituitary Growth". In Lissak K (ed.). Hormones and Brain Function. Springer Science & Business Media. pp. 145–. doi:10.1007/978-1-4684-2007-4_14. ISBN 978-1-4684-2007-4.
^ "Folivirin Injection". bbpharma.sk.
^ Talas M, Gazárak F, Stehliková J, Lubuský D, Fingerová H (1975). "FSH- und LH-Spiegel im Serum von Frauen nach chirurgischer Kastration und bei hormonaler Behandlung von Ausfallsbeschwerden" [Serum FSH and LH levels in women following surgical castration and during hormonal management of menopause symptoms]. Zentralbl Gynakol (in German). 97 (25): 1580–7. ISSN 0044-4197. PMID 1227215.
^ Kahr H, Müller HA (1956). "Behandlung der Menstruationsstörungen". Konservative Therapie der Frauenkrankheiten. pp. 1–85. doi:10.1007/978-3-7091-5694-0_1. ISBN 978-3-7091-5696-4.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[Folivirin-Label-1] "FOLIVIRIN Injekční suspenze, Příbalová Informace - Informace Pro Uživatele" [FOLIVIRIN Suspension for injection, Package Information - Information For Users] (PDF). Biotika A.S. (in Czech). Czech Republic: State Institute for Drug Control. Archived from the original (PDF) on 2019-05-20. Retrieved 2019-05-20.

[Kubíková2014-2] Kubíková D (2014). "Menopauzální symptomy a hormonální substituční terapie" [Menopausal symptoms and hormone replacement therapy]. Praktické Lékárenství (in Czech). 10 (2): 68–73. ISSN 1801-2434.

[Josefkolektiv2010-3] Josef M (14 May 2010). "Farmakoterapie endokrinních onemocnění a léčba kortikosteroidy" [Pharmacotherapy of endocrine diseases and treatment with corticosteroids]. Farmakoterapie vnitřních nemocí [Pharmacotherapy of internal diseases] (4th ed.). Grada Publishing a.s. pp. 380–. ISBN 978-80-247-9524-9. In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect.

[ArendsZörnig2013-4] Arends G, Zörnig H, Hager H, Frerichs G, Kern W (14 December 2013). Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1163–. ISBN 978-3-662-36329-4.

[HagerKern2013-5] Hager HH, Kern W, List PH, Roth HJ (29 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 109, 141, 178, 185. ISBN 978-3-662-25655-8.

[Ciba1953-6] Ciba Symposium: 1953/57:Index. Ciba. 1953. p. 197. Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone ; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines.

[Ae,_ppl.:iHerrmann1953-7] Aeppli H, Herrmann FU (1953). "Kombinierte Androgen-Oestrogenbehandlung mit Kristallsuspensionen". Gynecologic and Obstetric Investigation. 136 (5): 290–295. doi:10.1159/000308340. ISSN 1423-002X.

[HorskyPresl2012-8] Horsky J, Presl J (6 December 2012). "Climacteric and Menopause". Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 146–. ISBN 978-94-009-8195-9.

[Ufer1978-9] Ufer J (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis [Hormone Therapy in Gynecology: Principles and Practice] (in German) (5th ed.). de Gruyter. p. 276. ISBN 978-3110066647. OCLC 924728827.

[Drugs.com-Estradiol-10] "Estradiol: Uses, Dosage & Side Effects". Drugs.com.

[Drugs.com-Testosterone-11] "Testosterone Injections: Uses, Side Effects & Warnings". Drugs.com.

[Martindale2009-12] Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2133–2134. ISBN 978-0-85369-840-1.

[Micromedex-13] "Home". micromedexsolutions.com.

[pmid12988767-14] Drescher H (April 1952). "Unsere Erfahrungen mit einer neuartigen Testosteron-isobutyrat-Kristallsuspension" [Experiences with a New Testosterone Isobutyrate Crystal Suspension]. Dtsch. Med. Wochenschr. (in German). 77 (14): 431–2. doi:10.1055/s-0028-1115985. PMID 12988767.

[Lissak2012-15] Schreiber V (6 December 2012). "Thyroxine Binding to Anterior Pituitary Proteins in Vitro: Correlation with Anterior Pituitary Growth". In Lissak K (ed.). Hormones and Brain Function. Springer Science & Business Media. pp. 145–. doi:10.1007/978-1-4684-2007-4_14. ISBN 978-1-4684-2007-4.

[Folivirin-Depot-BB_Pharma-16] "Folivirin Injection". bbpharma.sk.

[pmid1227215-17] Talas M, Gazárak F, Stehliková J, Lubuský D, Fingerová H (1975). "FSH- und LH-Spiegel im Serum von Frauen nach chirurgischer Kastration und bei hormonaler Behandlung von Ausfallsbeschwerden" [Serum FSH and LH levels in women following surgical castration and during hormonal management of menopause symptoms]. Zentralbl Gynakol (in German). 97 (25): 1580–7. ISSN 0044-4197. PMID 1227215.

[KahrMüller1956-18] Kahr H, Müller HA (1956). "Behandlung der Menstruationsstörungen". Konservative Therapie der Frauenkrankheiten. pp. 1–85. doi:10.1007/978-3-7091-5694-0_1. ISBN 978-3-7091-5696-4.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

@@ Line 39: / Line 39: @@
 }}
-'''Estradiol benzoate/testosterone isobutyrate''' ('''EB/TiB'''), sold under the brand names '''Femandren M''' and '''Folivirin''', is an [[injection (medicine)|injectable]] [[combination drug|combination medication]] of [[estradiol benzoate]] (EB), an [[estrogen (medication)|estrogen]], and [[testosterone isobutyrate]] (TiB), an [[androgen]]/[[anabolic steroid]], which is used in [[menopausal hormone therapy]] for women.<ref name="Folivirin-Label">{{Cite web |url=http://www.sukl.cz/download/pil/PI15789.pdf |title=Archived copy |access-date=2019-05-20 |archive-date=2019-05-20 |archive-url=https://web.archive.org/web/20190520031642/http://www.sukl.cz/download/pil/PI15789.pdf |url-status=dead }}</ref><ref name="Kubíková2014">{{cite journal | last1 = Kubíková | first1 = Drahomíra | title = Menopauzální symptomy a hormonální substituční terapie | trans-title = Menopausal symptoms and hormone replacement therapy | language = cs | date = 2014 | journal = Praktické Lékárenství | volume = 10 | issue = 2 | pages = 68–73 | issn = 1801-2434 | url = http://www.medvik.cz/link/bmc14059249 <!-- | url2 = http://www.solen.sk/pdf/95e898d92100a736e32110dd1b846a9e.pdf-->}}</ref><ref name="Josefkolektiv2010">{{cite book|author1=Marek Josef|author2=a kolektiv|title=Farmakoterapie vnitřních nemocí: 4., zcela přepracované a doplněné vydání|url=https://books.google.com/books?id=bUqECwAAQBAJ&pg=PA380|date=14 May 2010|publisher=Grada Publishing a.s.|isbn=978-80-247-9524-9|pages=380–|quote=In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect.}}</ref><ref name="ArendsZörnig2013">{{cite book|author1=Georg Arends|author2=Heinrich Zörnig|author3=Hermann Hager|author4=Georg Frerichs, Walther Kern|title=Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte|url=https://books.google.com/books?id=8bLwBgAAQBAJ&pg=PA1163|date=14 December 2013|publisher=Springer-Verlag|isbn=978-3-662-36329-4|pages=1163–}}</ref><ref name="HagerKern2013">{{cite book|author1=Hans Hermann Julius Hager|author2=Walther Kern|author3=Paul Heinz List|author4=Hermann Josef Roth|title=Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL)|url=https://books.google.com/books?id=a2a0BgAAQBAJ&pg=PA141|date=29 July 2013|publisher=Springer-Verlag|isbn=978-3-662-25655-8|pages=109, 141, 178, 185}}</ref><ref name="Ciba1953">{{cite book|title=Ciba Symposium: 1953/57:Index|url=https://books.google.com/books?id=yQgbAQAAMAAJ|year=1953|publisher=Ciba|page=197|quote=Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone ; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines.}}</ref><ref name="Ae, ppl.:iHerrmann1953">{{cite journal|last1=Aeppli|first1=H.|last2=Herrmann|first2=F.U.|title=Kombinierte Androgen-Oestrogenbehandlung mit Kristallsuspensionen|journal=Gynecologic and Obstetric Investigation|volume=136|issue=5|year=1953|pages=290–295|issn=1423-002X|doi=10.1159/000308340}}</ref> It is provided in the form of 1&nbsp;mL [[ampoule]]s containing 2.5&nbsp;mg estradiol benzoate and 25&nbsp;mg testosterone isobutyrate in a [[microcrystalline]] [[aqueous suspension]] and is administered by [[intramuscular injection]] once every 4 to 6&nbsp;weeks.<ref name="Ciba1953" /><ref name="HorskyPresl2012">{{cite book|author1=J. Horsky|author2=J. Presl|title=Ovarian Function and its Disorders: Diagnosis and Therapy|url=https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA146|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-009-8195-9|pages=146–}}</ref> EB/TiB reportedly has a [[duration of action|duration]] of about 14 to 21&nbsp;days.<ref name="Ufer1978">{{cite book | last1 = Ufer | first1 = Joachim | title = Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis | trans-title = Hormone Therapy in Gynecology: Principles and Practice | edition = 5 | language = de | date = 1 January 1978 | isbn = 978-3110066647 | oclc = 924728827 | publisher = de Gruyter | page = 276}}</ref>
+'''Estradiol benzoate/testosterone isobutyrate''' ('''EB/TiB'''), sold under the brand names '''Femandren M''' and '''Folivirin''', is an [[injection (medicine)|injectable]] [[combination drug|combination medication]] of [[estradiol benzoate]] (EB), an [[estrogen (medication)|estrogen]], and [[testosterone isobutyrate]] (TiB), an [[androgen]]/[[anabolic steroid]], which is used in [[menopausal hormone therapy]] for women.<ref name="Folivirin-Label">{{Cite web |url=http://www.sukl.cz/download/pil/PI15789.pdf |title=FOLIVIRIN Injekční suspenze, Příbalová Informace - Informace Pro Uživatele | trans-title = FOLIVIRIN Suspension for injection, Package Information - Information For Users | work = Biotika A.S. | publisher = State Institute for Drug Control | location = Czech Republic | language = Czech |access-date=2019-05-20 |archive-date=2019-05-20 |archive-url=https://web.archive.org/web/20190520031642/http://www.sukl.cz/download/pil/PI15789.pdf |url-status=dead }}</ref><ref name="Kubíková2014">{{cite journal | vauthors = Kubíková D | title = Menopauzální symptomy a hormonální substituční terapie | trans-title = Menopausal symptoms and hormone replacement therapy | language = cs | date = 2014 | journal = Praktické Lékárenství | volume = 10 | issue = 2 | pages = 68–73 | issn = 1801-2434 | url = http://www.medvik.cz/link/bmc14059249 <!-- | url2 = http://www.solen.sk/pdf/95e898d92100a736e32110dd1b846a9e.pdf-->}}</ref><ref name="Josefkolektiv2010">{{cite book| vauthors = Josef M | chapter = Farmakoterapie endokrinních onemocnění a léčba kortikosteroidy | trans-chapter = Pharmacotherapy of endocrine diseases and treatment with corticosteroids |title=Farmakoterapie vnitřních nemocí | edition = 4th | trans-title = Pharmacotherapy of internal diseases | chapter-url=https://books.google.com/books?id=bUqECwAAQBAJ&pg=PA380|date=14 May 2010|publisher=Grada Publishing a.s.|isbn=978-80-247-9524-9|pages=380–|quote=In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect.}}</ref><ref name="ArendsZörnig2013">{{cite book| vauthors = Arends G, Zörnig H, Hager H, Frerichs G, Kern W |title=Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte|url=https://books.google.com/books?id=8bLwBgAAQBAJ&pg=PA1163|date=14 December 2013|publisher=Springer-Verlag|isbn=978-3-662-36329-4|pages=1163–}}</ref><ref name="HagerKern2013">{{cite book| vauthors = Hager HH, Kern W, List PH, Roth HJ |title=Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL)|url=https://books.google.com/books?id=a2a0BgAAQBAJ&pg=PA141|date=29 July 2013|publisher=Springer-Verlag|isbn=978-3-662-25655-8|pages=109, 141, 178, 185}}</ref><ref name="Ciba1953">{{cite book|title=Ciba Symposium: 1953/57:Index|url=https://books.google.com/books?id=yQgbAQAAMAAJ|year=1953|publisher=Ciba|page=197|quote=Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone ; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines.}}</ref><ref name="Ae, ppl.:iHerrmann1953">{{cite journal| vauthors = Aeppli H, Herrmann FU |title=Kombinierte Androgen-Oestrogenbehandlung mit Kristallsuspensionen|journal=Gynecologic and Obstetric Investigation|volume=136|issue=5|year=1953|pages=290–295|issn=1423-002X|doi=10.1159/000308340}}</ref> It is provided in the form of 1&nbsp;mL [[ampoule]]s containing 2.5&nbsp;mg estradiol benzoate and 25&nbsp;mg testosterone isobutyrate in a [[microcrystalline]] [[aqueous suspension]] and is administered by [[intramuscular injection]] once every 4 to 6&nbsp;weeks.<ref name="Ciba1953" /><ref name="HorskyPresl2012">{{cite book| vauthors = Horsky J, Presl J | chapter = Climacteric and Menopause |title=Ovarian Function and its Disorders: Diagnosis and Therapy| chapter-url = https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA146 |date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-009-8195-9|pages=146–}}</ref> EB/TiB reportedly has a [[duration of action|duration]] of about 14 to 21&nbsp;days.<ref name="Ufer1978">{{cite book | vauthors = Ufer J | title = Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis | trans-title = Hormone Therapy in Gynecology: Principles and Practice | edition = 5th | language = de | date = 1 January 1978 | isbn = 978-3110066647 | oclc = 924728827 | publisher = de Gruyter | page = 276}}</ref>
-The medication is available only in the [[Czech Republic]] and [[Slovakia]].<ref name="Drugs.com-Estradiol">{{Cite web|url=https://www.drugs.com/international/estradiol.html|title = Estradiol: Uses, Dosage & Side Effects}}</ref><ref name="Drugs.com-Testosterone">{{Cite web|url=https://www.drugs.com/international/testosterone.html|title = Testosterone Injections: Uses, Side Effects & Warnings}}</ref><ref name="Martindale2009">{{cite book | editor = Sweetman, Sean C. | chapter = Sex hormones and their modulators | title = Martindale: The Complete Drug Reference | edition = 36th | year = 2009 | pages = 2133–2134 | publisher = Pharmaceutical Press | location = London | isbn = 978-0-85369-840-1}}</ref><ref name="Micromedex">{{cite web |url=https://www.micromedexsolutions.com/ |title=Home |website=micromedexsolutions.com}}</ref> EB/TiB was originally developed and marketed by the [[Swiss people|Swiss]] [[pharmaceutical company]] [[Ciba Specialty Chemicals|Ciba]] and was introduced for medical use by 1953,<ref name="Ciba1953" /> following the development of testosterone isobutyrate in 1952.<ref name="pmid12988767">{{cite journal | vauthors = Drescher H | title = Unsere Erfahrungen mit einer neuartigen Testosteron-isobutyrat-Kristallsuspension | trans-title = Experiences with a New Testosterone Isobutyrate Crystal Suspension | language = de | journal = Dtsch. Med. Wochenschr. | volume = 77 | issue = 14 | pages = 431–2 | date = April 1952 | pmid = 12988767 | doi = 10.1055/s-0028-1115985 }}</ref> It was intermittently manufactured by Spofa<ref name="Lissak2012">{{cite book|author=K. Lissak|title=Hormones and Brain Function|url=https://books.google.com/books?id=7wX3BwAAQBAJ&pg=PA145|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4684-2007-4|pages=145–}}</ref> and then Biotika<ref name="Josefkolektiv2010" /> and is now manufactured by BB Pharma.<ref name="Drugs.com-Estradiol" /><ref name="Drugs.com-Testosterone" /><ref name="Folivirin-Depot-BB Pharma">{{Cite web|url=http://www.bbpharma.sk/hormones/folivirin-injection|title=Folivirin Injection - bbpharma.sk}}</ref>
+The medication is available only in the [[Czech Republic]] and [[Slovakia]].<ref name="Drugs.com-Estradiol">{{Cite web|url=https://www.drugs.com/international/estradiol.html|title = Estradiol: Uses, Dosage & Side Effects | work = Drugs.com }}</ref><ref name="Drugs.com-Testosterone">{{Cite web|url=https://www.drugs.com/international/testosterone.html|title = Testosterone Injections: Uses, Side Effects & Warnings | work = Drugs.com }}</ref><ref name="Martindale2009">{{cite book | veditors = Sweetman SC | chapter = Sex hormones and their modulators | title = Martindale: The Complete Drug Reference | edition = 36th | year = 2009 | pages = 2133–2134 | publisher = Pharmaceutical Press | location = London | isbn = 978-0-85369-840-1}}</ref><ref name="Micromedex">{{cite web |url=https://www.micromedexsolutions.com/ |title=Home |website=micromedexsolutions.com}}</ref> EB/TiB was originally developed and marketed by the [[Swiss people|Swiss]] [[pharmaceutical company]] [[Ciba Specialty Chemicals|Ciba]] and was introduced for medical use by 1953,<ref name="Ciba1953" /> following the development of testosterone isobutyrate in 1952.<ref name="pmid12988767">{{cite journal | vauthors = Drescher H | title = Unsere Erfahrungen mit einer neuartigen Testosteron-isobutyrat-Kristallsuspension | trans-title = Experiences with a New Testosterone Isobutyrate Crystal Suspension | language = de | journal = Dtsch. Med. Wochenschr. | volume = 77 | issue = 14 | pages = 431–2 | date = April 1952 | pmid = 12988767 | doi = 10.1055/s-0028-1115985 }}</ref> It was intermittently manufactured by Spofa<ref name="Lissak2012">{{cite book| vauthors = Schreiber V | chapter = Thyroxine Binding to Anterior Pituitary Proteins in Vitro: Correlation with Anterior Pituitary Growth | veditors = Lissak K |title=Hormones and Brain Function| chapter-url = https://books.google.com/books?id=7wX3BwAAQBAJ&pg=PA145|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4684-2007-4|pages=145– | doi = 10.1007/978-1-4684-2007-4_14 }}</ref> and then Biotika<ref name="Josefkolektiv2010" /> and is now manufactured by BB Pharma.<ref name="Drugs.com-Estradiol" /><ref name="Drugs.com-Testosterone" /><ref name="Folivirin-Depot-BB Pharma">{{Cite web|url=http://www.bbpharma.sk/hormones/folivirin-injection|title=Folivirin Injection | work = bbpharma.sk}}</ref>
 The effect of EB/TiB on [[gonadotropin]] levels in [[postmenopausal]] women have been studied.<ref name="pmid1227215">{{cite journal | vauthors = Talas M, Gazárak F, Stehliková J, Lubuský D, Fingerová H | title = FSH- und LH-Spiegel im Serum von Frauen nach chirurgischer Kastration und bei hormonaler Behandlung von Ausfallsbeschwerden | trans-title = Serum FSH and LH levels in women following surgical castration and during hormonal management of menopause symptoms | language = de | journal = Zentralbl Gynakol | volume = 97 | issue = 25 | pages = 1580–7 | date = 1975 | issn = 0044-4197 | pmid = 1227215 }}</ref>
-An [[oral administration|oral]] [[tablet (pharmacy)|tablet]] product with the same brand name of Femandren, containing [[ethinylestradiol]] and [[methyltestosterone]], was marketed around the same time as Femandren M, and should not be confused with the injectable formulation.<ref name="KahrMüller1956">{{cite book|last1=Kahr|first1=H.|last2=Müller|first2=H. A.|title=Konservative Therapie der Frauenkrankheiten|chapter=Behandlung der Menstruationsstörungen|year=1956|pages=1–85|doi=10.1007/978-3-7091-5694-0_1|isbn=978-3-7091-5696-4}}</ref><ref name="ArendsZörnig2013" /><ref name="HagerKern2013" />
+An [[oral administration|oral]] [[tablet (pharmacy)|tablet]] product with the same brand name of Femandren, containing [[ethinylestradiol]] and [[methyltestosterone]], was marketed around the same time as Femandren M, and should not be confused with the injectable formulation.<ref name="KahrMüller1956">{{cite book| vauthors = Kahr H, Müller HA |title=Konservative Therapie der Frauenkrankheiten|chapter=Behandlung der Menstruationsstörungen|year=1956|pages=1–85|doi=10.1007/978-3-7091-5694-0_1|isbn=978-3-7091-5696-4}}</ref><ref name="ArendsZörnig2013" /><ref name="HagerKern2013" />
 {{Androgen replacement therapy formulations and dosages used in women}}

Revision as of 06:06, 8 November 2023

See also

References